Stockreport

Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]

Monte Rosa Therapeutics, Inc.  (GLUE) 
PDF This compares to loss of $0.70 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 35.56 [Read more]